• Elicit Plant

  Led · Series B · Nov 2024

  Elicit Plant develops phytosterol-based biosolutions that reduce crop water use by about 20%, improving resilience to environmental stress. Its product portfolio targets maize, cereals, sunflower and soybeans. The company is led by CEO Jean-François Déchant and is based in Moulins-sur-Tardoire, Charente, France. Elicit Plant plans to accelerate R&D for advanced bio-based solutions and expand strategic alliances with partners such as Bayer and BASF. The company intends to use new funding to propel U.S. market entry by 2025 and to scale operations in Europe and Brazil. It recently completed a Series B to support its worldwide expansion strategy. Elicit Plant develops an innovative biostimulant based on phytosterol delivered via foliar application to boost plant metabolism and reduce water needs. Its proprietary technology was developed in laboratories on a precision farm in Charente, France, and at a Brazilian branch in São Paulo. Open-field trials and lab studies with independent researchers and farmers showed yield gains of up to +20%. The company obtained French market approval in April 2021 and launched its first BEST-a products for corn and soybean. Elicit Plant has about thirty employees across its headquarters/precision farm and its São Paulo branch. Proceeds from the recent financing will be used to accelerate commercialization in France and key markets in Europe, North America and South America, consolidate the scientific platform, expand laboratories, and diversify the product portfolio.

• Isotopen Technologien München

  Participated · Equity · Jun 2024

  ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech based in Garching, Germany focused on advancing radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. Its lead candidate is n.c.a. 177Lu-edotreotide (ITM-11 / 177Lu-edotreotide), and the company supports a broad precision oncology pipeline including multiple Phase 3 studies. The company is led by CEO Dr. Andrew Cavey. ITM plans to use new capital to prepare for commercial readiness and potential market launch of its lead candidate. The company announced a non-dilutive debt financing agreement that will support late-stage development and commercial preparation. ITM is a radiopharmaceutical biotech company dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. Led by CEO Steffen Schuster and based in Munich, Germany, the company focuses on advancing radiopharmaceutical candidates. ITM intends to use the funds to advance and expand its radiopharmaceutical pipeline and to foster its development platform. The company will prepare commercial readiness for the potential market launch of its phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Proceeds will also enable expansion of manufacturing capabilities for production of alpha- and beta-emitting radioisotopes, including Lutetium-177(177Lu) and Actinium-225(225Ac). ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech focused on radiomolecular precision therapeutics and diagnostics (theranostics) and a broad Targeted Radionuclide Therapies (TRT) oncology pipeline. Its lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) is nearing the final stages of phase III development in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and ITM-31 (Lu-177 labeled 6A10 Fab-fragments) is in clinical studies for glioblastoma. The company is also a major radioisotope supplier and is expanding manufacturing and GMP capabilities for n.c.a. 177Lu and scaling GMP manufacturing for 225Ac to meet growing demand. Planned investments include a second state-of-the-art manufacturing facility in Germany, expanded in-house drug product manufacturing, and broader commercial infrastructure to accelerate global access. ITM has opened a U.S. headquarters in Princeton, New Jersey and established a subsidiary in Shanghai to support regional introduction of precision oncology products. The company says it will leverage nearly two decades of radiopharma expertise and its global network to improve patient access to targeted treatments. ITM develops targeted radiopharmaceutical diagnostics and therapeutics by combining medical radioisotopes with targeting molecules to treat hard-to-treat cancers. The company produces and supplies high-quality medical radioisotopes through a wide-reaching international supply network and leverages nearly two decades of radiopharma expertise. Its lead therapeutic candidate, ITM-11 (n.c.a. 177Lu-edotreotide), is being evaluated in two phase III trials (COMPETE and COMPOSE) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to use recent financing to finalize late-stage development of ITM-11, support potential commercialization and market launch efforts if approved, accelerate development of additional radiopharmaceutical candidates, and expand radioisotope supply capabilities. The company emphasizes precision oncology approaches that deliver radiation directly to tumors while minimizing exposure to healthy tissue. ITM is positioned as a global player in nuclear medicine, aiming to advance a broad proprietary pipeline and enable wider clinical adoption of targeted radionuclide therapies. ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company focused on development, production and global supply of targeted radionuclide diagnostics and therapeutics. The company produces high-quality medical radioisotopes and leverages nearly two decades of radiopharma expertise and an established global supply network. ITM has forward-integrated to build a broad pipeline, including lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) which is undergoing two phase III trials (COMPETE and COMPOSE), and companion diagnostic TOCscan® (68Ga-edotreotide). ITM-41 (n.c.a. 177Lu-zoledronate) is in preclinical development for osteosarcoma and bone metastases. The company is focused on expanding its presence in Asia and Greater China to meet growing patient needs. A recent strategic equity investment is intended to support late-stage development and broader commercialization efforts in the region.

• Fotokite

  Led · Series B · Apr 2024

  Fotokite develops tethered, autonomous drones for firefighting and emergency response, aimed at improving situational awareness for first responders. The company's core product is tethered UAV technology used to support search and rescue and emergency operations. With recent expansion across six continents, Fotokite has positioned itself as a global provider of aerial emergency solutions. Management plans to use new capital to broaden its reach and enhance its autonomous firefighting capabilities. The company highlights goals to streamline search and rescue workflows and save lives in critical situations. CEO Bart Slager expressed excitement about the future impact of Fotokite's solutions on first responders and communities worldwide. Fotokite (Perspective Robotics AG) develops the Fotokite Sigma, a self‑piloting, actively tethered aerial device that provides immediate overhead situational awareness to firefighting and public‑safety teams. The system is positioned to deliver aerial capabilities without the safety issues and operational inefficiencies of traditional drones. The company says the CHF 13.7 million Series B will help scale operations, bolster its in‑house engineering team, and drive sales in North American and European markets. Fotokite has strengthened its presence in the United States and Canada and expanded its fleet across major European markets including Switzerland, Germany, France and the United Kingdom. The company reports increasing regional accessibility of Fotokite Sigma systems to public‑safety teams across 17 European countries. Fotokite has been recognized among TOP 100 Swiss Startups (2017–2019) and as a Venture Leader in 2018 and 2022. Perspective Robotics, an ETH Zurich spinoff, develops the Fotokite, a tethered and autonomous drone system for public safety teams. The Fotokite flies on a tether and operates autonomously, reducing the need for piloting and letting responders focus on missions. Its tethered design is safe for use above crowds and in urban environments, which the company cites as an advantage over free‑flying drones. Perspective Robotics has secured regulatory advantages for its technology in the US, Switzerland, and France. The company says the recent investment led by Credit Suisse Entrepreneur Capital Ltd. will fuel growth, create new jobs, and accelerate efforts to improve situational information for firefighters and first responders. The funding was provided by Credit Suisse's Entrepreneur Capital vehicle, which manages CHF 200 million and has added Perspective Robotics to a portfolio of 50 companies. Fotokite is a Swiss startup that combines aerial and ground-based robotics with patented flight-control algorithms to create a kite-like tethered drone system. The drone actively uses its tether to fly fully autonomously for 24 hours while delivering an aerial data livestream to the ground. Fotokite has obtained FAA approval to commercialise its drone in U.S. cities. The company is adding a live aerial situational-awareness application for firefighters and has signed a contract with a large U.S. fire-truck manufacturer. Fotokite plans to expand its sales and business-development team to New York while its Swiss team continues to focus on research and development. The startup says it will use the GENIUS NY funding to accelerate growth and U.S. expansion. Perspective Robotics AG develops the Fotokite Phi, a very light, tethered quadcopter designed to carry GoPro cameras for consumer photography and hobby use. The Fotokite design emphasizes safety and ease of use through a physical tether that keeps the aircraft aware of and attached to the operator. CEO Sergei Lupashin originally demonstrated the underlying technology on the TED stage in 2014, and a tethered Fotokite variant is already used by major news outlets such as the BBC for broadcast coverage. The company positioned the Phi as a more affordable, consumer-friendly Fotokite by reducing manufacturing costs made possible by the tether. The product is described as a cross between an airborne pet and a steadicam, intended for photography, hobbyists, and casual use. As of the article, the company achieved crowdfunding support and is running an Indiegogo campaign to fund production of the Phi.

No current team members are available.